Showing 1 - 16 of 16 Items
Showing 1 - 16 of 16 Items
Sort By: Relevance
Journal Article
|Research
2025-02-01 • Lancet Child and Adolescent Health
2025-02-01 • Lancet Child and Adolescent Health
BACKGROUND
There are few data on the treatment of children and adolescents with multidrug-resistant (MDR) or rifampicin-resistant (RR) tuberculosis, especially ...
Journal Article
|Commentary
2023-07-31 • Lancet Microbe
2023-07-31 • Lancet Microbe
Journal Article
|Commentary
2023-01-01 • Nature Medicine
2023-01-01 • Nature Medicine
Journal Article
|Research
2015-02-01 • International Journal of Tuberculosis and Lung Disease
2015-02-01 • International Journal of Tuberculosis and Lung Disease
SETTING
The cost of multidrug-resistant tuberculosis (MDR-TB) treatment is a major barrier to treatment scale-up in South Africa.
OBJECTIVE
To estimate and compare the c...
The cost of multidrug-resistant tuberculosis (MDR-TB) treatment is a major barrier to treatment scale-up in South Africa.
OBJECTIVE
To estimate and compare the c...
Journal Article
|Research
2020-03-20 • European Respiratory Journal
2020-03-20 • European Respiratory Journal
We sought to compare the effectiveness of two World Health Organization (WHO)-recommended regimens for the treatment of rifampin- or multidrug-resistant (RR/MDR) tuberculosis (TB): a sta...
Journal Article
|Research
2022-05-02 • Lancet Infectious Diseases
2022-05-02 • Lancet Infectious Diseases
BACKGROUND
There is a need for short and safe all-oral treatment of rifampicin-resistant tuberculosis. We compared outcomes up to 24 months after treatment initiation for patients wi...
There is a need for short and safe all-oral treatment of rifampicin-resistant tuberculosis. We compared outcomes up to 24 months after treatment initiation for patients wi...
Journal Article
|Research
2021-11-12 • Lancet Infectious Diseases
2021-11-12 • Lancet Infectious Diseases
BACKGROUND
Bedaquiline improves outcomes of patients with rifampicin-resistant and multidrug-resistant (MDR) tuberculosis; however, emerging resistance threatens this success. We did...
Bedaquiline improves outcomes of patients with rifampicin-resistant and multidrug-resistant (MDR) tuberculosis; however, emerging resistance threatens this success. We did...
Journal Article
|Research
2018-09-08 • Lancet
2018-09-08 • Lancet
BACKGROUND
Treatment outcomes for multidrug-resistant tuberculosis remain poor. We aimed to estimate the association of treatment success and death with the use of individual drugs, ...
Treatment outcomes for multidrug-resistant tuberculosis remain poor. We aimed to estimate the association of treatment success and death with the use of individual drugs, ...
Journal Article
|Research
2020-10-01 • International Journal of Tuberculosis and Lung Disease
2020-10-01 • International Journal of Tuberculosis and Lung Disease
Worldwide uptake of new drugs in the treatment of rifampicin-resistant tuberculosis (RR-TB) has been extremely low. In June 2018, ahead of the release of the updated WHO guidelines for t...
Journal Article
|Research
2018-10-25 • European Respiratory Journal
2018-10-25 • European Respiratory Journal
Background: South African patients with rifampicin-resistant tuberculosis and resistance to fluoroquinolones and/or injectables (pre/XDR-TB) were granted access to bedaquiline through a ...
Journal Article
|Research
2015-07-19 • International Journal of Tuberculosis and Lung Disease
2015-07-19 • International Journal of Tuberculosis and Lung Disease
BACKGROUND
South Africa has a large burden of extensively drug-resistant tuberculosis (XDR-TB); only 15% of XDR-TB patients have successful outcomes.
OBJECTIVE
To descri...
South Africa has a large burden of extensively drug-resistant tuberculosis (XDR-TB); only 15% of XDR-TB patients have successful outcomes.
OBJECTIVE
To descri...
Journal Article
|Research
2020-02-01 • International Journal of Infectious Diseases
2020-02-01 • International Journal of Infectious Diseases
The continuous flow of new research articles on MDR-TB diagnosis, treatment, prevention and rehabilitation requires frequent update of existing guidelines. This review is aimed at provid...
Journal Article
|Research
2018-09-01 • Lancet Respiratory Medicine
2018-09-01 • Lancet Respiratory Medicine
Addition of bedaquiline to treatment for multidrug-resistant tuberculosis was associated with an increased risk of death in a phase 2b clinical trial, resulting in caution from WHO. Foll...
Journal Article
|Letter
2020-07-23 • European Respiratory Journal
2020-07-23 • European Respiratory Journal
Rapid adoption of new diagnostic tools, parallel process of research and implementation, decentralisation of services, the use of personal protective equipment, as well as strong partner...
Journal Article
|Commentary
2014-03-01 • South African Medical Journal
2014-03-01 • South African Medical Journal
While clinical disease caused by drug-sensitive Mycobacterium tuberculosis (MTB) can usually be treated successfully, clinical disease caused by drug-insensitive MTB is associated with a...
Journal Article
|Research
2017-02-01 • International Journal of Tuberculosis and Lung Disease
2017-02-01 • International Journal of Tuberculosis and Lung Disease
BACKGROUND
For the first time in almost 50 years, there are new drugs available for the treatment of tuberculosis (TB), including bedaquiline (BDQ) and delamanid (DLM). The rate of i...
For the first time in almost 50 years, there are new drugs available for the treatment of tuberculosis (TB), including bedaquiline (BDQ) and delamanid (DLM). The rate of i...